Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high29.00 07/03/17
52 week low17.25 26/09/16
52 week change -2.25 (-8.53%)
4 week volume3,743,010 26/02/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Allergy Therapeutics recruits first patient in birch pollen trial

Allergy Therapeutics has recruited the first patient in its phase III study designed to evaluate the efficacy and safety of its u...

First Patient in Pivotal Phase III Birch Study

RNS Number: 6158Z Allergy Therapeutics PLC 16 March 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 16 March 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccin...

Notice of Interim Results

RNS Number: 9163Y Allergy Therapeutics PLC 09 March 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Notice of Interim Results 9 March 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its interim results for the six months ended 31 December 2016 on Wedn...

Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLC

Stifel today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and set its price target at 60p.

Allergy Therapeutics vaccine gains CTA spproval

Allergy Therapeutics has received approval for a clinical study of its novel house dust mite allergy vaccine. The company s...

House Dust Mite Allergy Vaccine Gains CTA Approval

RNS Number: 7777W Allergy Therapeutics PLC 14 February 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval CTA approval in Spain for Phase I AM101 clinical study evaluating safety of adjuvanted, modified house dust mite allergy v...

Directorate Change

RNS Number: 2838W Allergy Therapeutics PLC 08 February 2017 8 February 2 0 17 A l l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he ' C o m p a n y " ) Directorate Change Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces the appointment of Mr Jeff Barton t...

Allergy Therapeutics positive data in peanut allergy vaccine

Allergy Therapeutics has announced positive results from preclinical research into its unique therapeutic peanut allergy va...

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...
hardman & co
Allergy Therapeutics plc
07/06/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. It’s lead product, Pollinex Quattro is available in Europe only on a ‘Named Patient’ basis. However,...

Latest discussion posts More

  • TWO POTENTIAL GOLD NUGGETS IN THE RNS

    If approved, Pollinex Quattro Birch will be the "first" MPL adjuvanted ultra-short course aluminium-free vaccine ever approved. "Combined with our clinical programme in ...
    16-Mar-2017
    Baffler
  • Notice of Interim Results

    Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Notice of Interim Results 9 March 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty ...
    9-Mar-2017
    Totally Wired
  • Interviews

    This is taken from another ...
    15-Feb-2017
    Baffler

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.26%
BARCLAYS17%
BP17%
SIRIUS MINERALS15%
NATIONAL GRID14%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY